Health economic assessment of the ATAC trial comparing anastrozole versus tamoxifen in adjuvant treatment of postmenopausal hormone receptor positive early breast cancer

被引：3

作者：

Annemans, L

Moeremans, K

Lamarque, H

机构：

[1] State Univ Ghent, HEDM, Meise, Belgium

[2] Astrazeneca, Rueil Malmaison, France

来源：

VALUE IN HEALTH | 2003年 / 6卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)61604-X

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：625 / 625

页数：1

共 50 条

[1] Health economic evaluation based on the 5-year completed treatment analysis of the ATAC trial comparing anastrozole versus tamoxifen in adjuvant treatment of postmenopausal hormone receptor positive early breast cancer
Moeremans, K
Annemans, L
VALUE IN HEALTH, 2005, 8 (06) : A21 - A22
[2] Cost-effectiveness of anastrozole versus tamoxifen as adjuvant therapy for postmenopausal women with early hormone-receptor positive breast cancer - an evaluation of the ATAC-trial.
Lundkvist, J.
Paulsson, T.
Borgstrom, F.
Kasteng, F.
Sobocki, P.
Lidgren, M.
Henriksson, R.
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S229 - S229
[3] Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M
Buzdar, AU
Cuzick, J
Forbes, J
Houghton, J
Klijn, JGM
Sahmoud, T
LANCET, 2002, 359 (9324): : 2131 - 2139
[4] ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial-anastrozole is superior to tamoxifen as adjuvant treatment in postmenopausal women with early breast cancer.
Bianco, R
BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S155 - S155
[5] Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole
Menada, Mario Valenzano
Costantini, Sergio
Moioli, Melita
Bogliolo, Stefano
Papadia, Andrea
Ferrero, Simone
Dugnani, Maria Cristina
BREAST, 2008, 17 (06): : 631 - 636
[6] Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial
Kurosumi, Masafumi
Takatsuka, Yuichi
Watanabe, Toru
Imoto, Shigeru
Inaji, Hideo
Tsuda, Hitoshi
Akiyama, Futoshi
Sakamoto, Goi
Ikeda, Tadashi
Noguchi, Shinzaburo
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (06) : 715 - 722
[7] Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial
Masafumi Kurosumi
Yuichi Takatsuka
Toru Watanabe
Shigeru Imoto
Hideo Inaji
Hitoshi Tsuda
Futoshi Akiyama
Goi Sakamoto
Tadashi Ikeda
Shinzaburo Noguchi
Journal of Cancer Research and Clinical Oncology, 2008, 134 : 715 - 722
[8] Anastrozole is superior to tamoxifen in the treatment of postmenopausal women with early breast cancer - first results of the ATAC ('Arimidex', Tamoxifen, alone or in combination) trial
Sainsbury, R
INTERNATIONAL JOURNAL OF CANCER, 2002, : 137 - 137
[9] Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer
Aydiner, Adnan
Tas, Faruk
TRIALS, 2008, 9 (1)
[10] Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer
Adnan Aydiner
Faruk Tas
Trials, 9

← 1 2 3 4 5 →